Literature DB >> 7077088

Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis.

A Zwahlen, U E Nydegger, P Vaudaux, P H Lambert, F A Waldvogel.   

Abstract

A local defense mechanism in bacterial meningitis was evaluated in humans by measuring complement-mediated opsonic activity (CMOA) in normal and infected cerebrospinal fluid (CSF) with a complement-dependent phagocytic bactericidal assay. CMOA was absent in normal untreated CSF and remained undetectable in 20 samples of CSF from patients with viral meningitis and five samples from patients with acute meningococcemia. In contrast, 15 of 27 samples of CSF from patients with acute bacterial meningitis had a measurable CMOA, which was correlated with protein concentrations (P less than 0.01) and C4 hemolytic activity (P less than 0.001) in the CSF. A favorable outcome of bacterial meningitis was associated with the presence of CMOA in CSF (P less than 0.005). Recovery was also correlated with higher levels of C4 (P less than 0.01) and C3 (P less than 0.05) in CSF and with lower concentrations of microorganisms in the sample of CSF collected at the time of admission (P less than 0.01). Thus, CMOA, although absent in normal CSF, can appear in CSF during acute bacterial meningitis, particularly in patients who recover completely.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7077088     DOI: 10.1093/infdis/145.2.635

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  25 in total

1.  Bacterial Meningitis: Principles and Practical Aspects of Therapy.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

2.  Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis.

Authors:  P F Stahel; K Frei; A Fontana; H P Eugster; B H Ault; S R Barnum
Journal:  Am J Pathol       Date:  1997-10       Impact factor: 4.307

Review 3.  Chemotactic factors in cerebrospinal fluid during bacterial meningitis.

Authors:  Petra J G Zwijnenburg; Tom van der Poll; John J Roord; A Marceline van Furth
Journal:  Infect Immun       Date:  2006-03       Impact factor: 3.441

4.  Genome-wide identification of Streptococcus pneumoniae genes essential for bacterial replication during experimental meningitis.

Authors:  T E Molzen; P Burghout; H J Bootsma; C T Brandt; Christa E van der Gaast-de Jongh; M J Eleveld; M M Verbeek; N Frimodt-Møller; C Østergaard; P W M Hermans
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

5.  CD14 receptor-mediated uptake of nonopsonized Mycobacterium tuberculosis by human microglia.

Authors:  P K Peterson; G Gekker; S Hu; W S Sheng; W R Anderson; R J Ulevitch; P S Tobias; K V Gustafson; T W Molitor; C C Chao
Journal:  Infect Immun       Date:  1995-04       Impact factor: 3.441

6.  Independence of neutrophil respiratory burst oxidant generation from the early cytosolic calcium response after stimulation with unopsonized Candida albicans hyphae.

Authors:  D R Wysong; C A Lyman; R D Diamond
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

Review 7.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

8.  Role of cerebrospinal fluid pleocytosis and Haemophilus influenzae type b capsule on blood brain barrier permeability during experimental meningitis in the rat.

Authors:  A J Lesse; E R Moxon; A Zwahlen; W M Scheld
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

9.  Magnitude of bacteremia and complement activation during Neisseria meningitidis infection: study of two co-primary cases with different clinical presentations.

Authors:  A Zwahlen; F A Waldvogel
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

Review 10.  Treatment of bacterial meningitis.

Authors:  U B Schaad
Journal:  Eur J Clin Microbiol       Date:  1986-10       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.